This article has Open Peer Review reports available.
Extensive myelitis associated with anti-NMDA receptor antibodies
© Outteryck et al.; licensee BioMed Central Ltd. 2013
Received: 8 October 2013
Accepted: 18 December 2013
Published: 27 December 2013
Encephalitis with anti-N-methyl-D-aspartate receptor antibodies (anti-NMDAR-Ab) is a rapid-onset encephalitis including psychosis, seizures, various movement disorders and autonomic system disturbances.
We report a very unusual case of extensive myelitis associated with anti-NMDAR-Ab. MRI also revealed a hyperintense T2 lesion, non-suggestive of MS, which progressively extended, associated with periventricular gadolinium enhancement visualized on brain MRI. Ophthalmological evaluation showed subclinical right optic neuritis. The absence of anti-AQP4 antibody argued against neuromyelitis optica spectrum disorder. A slight psychomotor slowing prompted us to search for various causes of autoimmune encephalitis. Anti-NMDAR-Ab was found in cerebrospinal fluid.
In patients with extensive myelitis who are seronegative for anti-AQP4 antibodies, and after other classical causes have been excluded, the hypothesis of atypical anti-NMDAR-Ab encephalitis should also be considered.
Encephalitis with anti-N-methyl-D-aspartate receptor antibodies (anti-NMDAR-Ab) is a rapid-onset encephalitis including psychosis, seizures, various movement disorders and autonomic system disturbances. The physiopathology is based on immune-mediated neuronal dysfunction [1, 2]. We report the case of a 65-year-old woman presenting an extensive myelitis associated with anti-NMDAR-Ab.
A 65-year-old woman was admitted because of progressive paraparesis (June 2012). Six months before admission, she had presented with fever, chills, abdominal pain and unusual headache for one week with spontaneous recovery. Abdomen and brain MRI were normal at that time. Two months before admission, she described a progressive onset of walking difficulties. At the same time, constipation and dysuria were noted. At her admission, neurological examination noted walking difficulties related to moderate paraparesis, moderate superficial and deep sensory dysfunction of the lower limbs and urinary retention. A very slight dysfunction of mental processing without speech disturbance was noted and confirmed by her family. No seizures, dyskinesia, movement disorders, psychiatric symptoms or autonomic dysfunction were observed.
Anti-NMDA-R follow-up of the titration in CSF and in serum (qualitative and quantitative)
Anti-NMDA-R in serum
Methylprednisolone (1 g/day IV)
Rituximab (375 mg/m2/week during 4 weeks)
Our patient presented extensive myelitis associated with anti-NMDAR-Ab leading us to discuss a possible atypical form of anti-NMDAR-Ab encephalitis. Spinal cord symptoms were prominent throughout the clinical stage and were consistent with the extensive myelitis detected on spinal cord MRI. Slight psychomotor retardation is not sufficient to affirm that our patient presented anti-NMDAR-Ab encephalitis but early treatment might have stopped its development. Brain MRI showed hyperintense T2 lesions but also ventriculitis aspect. In view of the combination of extensive myelitis, brain T2 lesions non-suggestive of MS, ventriculitis aspect on MRI and subclinical ON, our first hypothesis was myelitis as a first event of neuromyelitis optica (NMO) or NMO spectrum disorder (NMOSD). Although cognitive disturbances are described in NMO , we also looked for other conditions involving auto-immune encephalitis and found anti-NMDAR-Ab in the CSF before immunosuppressive drugs had been applied.
Prodromal symptoms such as headache and fever are common  but we noted 3 atypical events for the hypothesis of anti-NMDAR-Ab encephalitis. First, myelitis is a very rare manifestation during anti-NMDAR-Ab encephalitis but has already been described [4–6]. In these 3 previous cases, all patients presented severe psychiatric or behavioural symptoms before the spinal cord syndrome and the encephalopathic symptoms remained prominent during all stages of the disease. In our case, the spinal cord syndrome remained prominent from the beginning and extension of the hyperintense T2 lesion was greater. Secondly, we highlighted in our case ventriculitis associated with meningeal Gd enhancement. Meningeal contrast enhancement in anti-NMDAR-Ab encephalitis is rare and [7, 8], to the best of our knowledge, the ventriculitis aspect has never previously been described. NMDA receptors are membrane receptors widely expressed in the central nervous system on various cells such as neurons, oligodendrocytes but also astrocytes . The ependymal regions contain ependymal cells and astrocytes rich in AQP4, and can also be involved in NMO, as described in 2 previously reported cases with thin ependymal and periventricular Gd enhancement [10, 11]. Thirdly, our patient presented right subclinical ON. Since the prodromal symptoms dated back 6 months, it seems likely that the demyelinating pathology had already started 6 months before the spinal cord syndrome. RNFL atrophy most often (>94 %) appears within the 6 months after ON . ON has only once been reported as a neurological manifestation of anti-NMDAR-Ab encephalitis .
Even though some correlations have been found between clinical status and anti-NMDAR-Ab titres in CSF, there is no reported correlation with anti-NMDAR-Ab titres in serum, and we therefore do not recommend a follow-up of anti-NMDAR-Ab titres in serum [1, 14].
Anti-NMDAR-Ab encephalitis has been described following massive brain damage induced by herpes simplex encephalitis (HSE) [15, 16]. Anti-NMDAR-Ab has also been found in sera of systemic lupus erythematosus and might be predictive of neuropsychiatric manifestations . In the present case report, we cannot affirm that our patient presented anti-NMDAR-Ab encephalitis because of encephalopathic symptoms lacking and also cannot exclude that a massive brain and spinal damage of unknown etiology has led to secondary immunological response with anti-NMDA-R Ab production.
We can also discuss the hypothesis that our patient may have presented 2 auto-immune diseases concurrently: an NMOSD and an anti-NMDAR-Ab encephalitis. These are both Ab-mediated diseases and a comorbid association of auto-immune diseases is possible. Recently a case of NMO (seropositive anti-AQP4 Ab) following anti-NMDAR-Ab encephalitis has been described . As our patient was seronegative for anti-AQP4 Ab and presented only subclinical ON, we cannot conclusively confirm or rule out this hypothesis.
In patients with extensive myelitis who are seronegative for anti-AQP4 Ab, and after other classical causes have been excluded, the hypothesis of atypical anti-NMDAR-Ab encephalitis should also be considered.
Written informed consent was obtained from the husband of the patient for publication of this Case report and the accompanying images. A copy of the written consent is available for review by the editor of this journal.
- Dalmau J, Lancaster E, Martinez-Hernandez E, et al: Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011, 10: 63-74. 10.1016/S1474-4422(10)70253-2.View ArticlePubMedPubMed CentralGoogle Scholar
- Misakova L, De Rossi P, Bouchet D, et al: Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain. 2012, 135: 1606-1621. 10.1093/brain/aws092.View ArticleGoogle Scholar
- Blanc F, Zéphir H, Lebrun C, et al: Cognitive functions in neuromyelitis optica. Arch Neurol. 2008, 65: 84-88.PubMedGoogle Scholar
- Taylor RB, Mason W, Kong K, et al: Reversible paraneoplastic encephalomyelitis associated with a benign ovarian teratoma. Can J neurol Sci. 1999, 26: 317-320.View ArticlePubMedGoogle Scholar
- Kruer MC, Koch TK, Bourdette DN, et al: NMDA receptor encephalitis mimicking seronegative neuromyelitis optica. Neurology. 2010, 74: 1473-1475. 10.1212/WNL.0b013e3181dc1a7f.View ArticlePubMedPubMed CentralGoogle Scholar
- Lekoubou A, Viaccoz A, Didelot A, et al: Anti-N-methyl-D-aspartate receptor encephalitis with acute disseminated encephalomyelitis-like MRI features. Eur J Neurol. 2012, 19: e16-e17. 10.1111/j.1468-1331.2011.03617.x.View ArticlePubMedGoogle Scholar
- Dalmau J, Tüzün E, Wu HY, et al: Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007, 61: 25-36. 10.1002/ana.21050.View ArticlePubMedPubMed CentralGoogle Scholar
- Dalmau J, Gleichman AJ, Hughes EG, et al: Anti-NMDA-receptor encephalitis: case series and analysis of the effect of antibodies. Lancet Neurol. 2008, 7: 1091-1098. 10.1016/S1474-4422(08)70224-2.View ArticlePubMedPubMed CentralGoogle Scholar
- Paoletti P, Bellone C, Zhou Q: NMDA receptor subunit diversity: impact on receptor properties synaptic plasticity and disease. Nat Rev Neurosci. 2013, 14: 383-400. 10.1038/nrn3504.View ArticlePubMedGoogle Scholar
- Pittock SJ, Weinshenker BG, Lucchinetti CF, et al: Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006, 63: 964-968. 10.1001/archneur.63.7.964.View ArticlePubMedGoogle Scholar
- Banker P, Sonni S, Kister I, et al: Pencil-thin ependymal enhancement in neuromyelitis optica spectrum disorders. Mult Scler. 2012, 18: 1050-1053. 10.1177/1352458511431730.View ArticlePubMedGoogle Scholar
- Costello F, Coupland S, Hodge W, et al: Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol. 2006, 59: 963-969. 10.1002/ana.20851.View ArticlePubMedGoogle Scholar
- Ishikawa N, Tajima G, Hyodo S, et al: Detection of autoantibodies against NMDA-type glutamate receptor in a patient with recurrent optic neuritis and transient cerebral lesions. Neuropediatrics. 2007, 38: 257-260. 10.1055/s-2007-1004521.View ArticlePubMedGoogle Scholar
- Frechette ES, Zhou L, Galetta SL, et al: Prolonged follow-up and CSF antibody titers in a patient with anti-NMDA receptor encephalitis. Neurology. 2011, 76: S64-S66. 10.1212/WNL.0b013e31820c34de.View ArticlePubMedGoogle Scholar
- Pruss H, Finke C, Höltje M, Hofmann J, Klingbeil C, Probst C, Borowski K, Ahnert-Hilger G, Harms L, Scwab JM, Ploner CJ, Koromowski L, Stoecker W, Dalmau J, Wandiger KP: N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol. 2012, 72: 902-911. 10.1002/ana.23689.View ArticlePubMedPubMed CentralGoogle Scholar
- Armangue T, Leypoldt F, Málaga I, Raspall-Chaure M, Marti I, Nichter C, et al: Herpes Simplex Virus Encephalitis is a Trigger of Brain Autoimmunity. Ann Neurol. 2013, doi:10.1002/ana.24083. epub ahead of printGoogle Scholar
- Gono T, Kawaguchi Y, Kaneko H, Nishimura K, Hanaoka M, Kataoka S, et al: Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupus erythematosus. Rheumatology. 2011, 50: 1578-1585. 10.1093/rheumatology/keq408.View ArticlePubMedGoogle Scholar
- Zoccarato M, Saddi MV, Serra G, Pelizza MF, Rosellini I, Peddone L, Ticca A, Giometto B, Zuliani L: Aquaporin-4 antibody neuromyelitis optica following anti-NMDA receptor encephalitis. J Neurol. 2013, 260: 3185-3187. 10.1007/s00415-013-7182-x.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2377/13/211/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.